Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Renal Structural and Functional Alterations Following Repeated Ureteroscopic Procedures: An Exploratory Multimodal Imaging Study (BackFlow2)

28 de outubro de 2026 atualizado por: Emmeli Grøne Lykkegaard, Region of Southern Denmark

Introduction and objectives

Saline irrigation and instrumentation during Retrograde Intrarenal Surgery (RIRS) causes elevation of intrarenal pressure (IRP) inducing intrarenal backflow (IRB). In an experimental study from 2025 Hinojosa-Gonzalez et al. demonstrated an association between elevated IRP and increased risk of bacteremia. The potential of elevated IRP and IRB to breach physiological barriers and facilitate systemic translocation of renal pelvic contents warrants investigation into their effects on parenchymal integrity and function.

Using contrast-enhanced MRI in a porcine model, Lildal et al. (2023) demonstrated segmental IRB with sharply demarcated areas of contrast distribution, predominantly at the renal poles. The preferential involvement of renal poles resembles the distribution of renal scarring observed in reflux nephropathy, raising the hypothesis that repeated pressure-related exposure may contribute to localized parenchymal alterations.

However, whether repeated ureteroscopic procedures are associated with similar persistent regional changes in renal structure and function remains unclear.

We therefore initiated an exploratory clinical study assessing renal structure and function following multiple ureteroscopic procedures using multiparametric MRI, DMSA scintigraphy and ultrasound elastography.

Materials and methods

This exploratory cross-sectional case-control study aims to enroll 10 patients with repeated unilateral ureteroscopic procedures and 10 healthy controls. Eligible patients must have undergone ≥3 ipsilateral procedures (RIRS/URS/URSL) and ≤1 contralateral procedure. Major exclusions include solitary kidney, metabolic or structural renal disorders compromising MRI analysis, chronic UTI, previous multiple PCNL procedures, and MRI contraindications.

All participants undergo serum creatinine measurement and multiparametric renal MRI (1.5T Philips Ingenia), including T1 mapping, heavily T2-weighted 3D imaging, diffusion-weighted imaging, T2* imaging, and renal arterial flow assessment. Renal scintigraphy is performed using ⁹⁹ᵐTc-DMSA, with planar imaging for quantification of split renal function and SPECT for evaluation of cortical scarring. Bilateral renal shear-wave elastography (Mindray Resona I9 ultrasound system) is conducted to quantify regional parenchymal stiffness in five predefined regions per kidney.

Planned analyses will compare regional imaging parameters between patients and controls and between ipsilateral and contralateral kidneys, accounting for within-subject correlation. Segmental imaging parameters will be compared between groups and kidneys using linear mixed-effects models accounting for repeated measurements within subjects.

Visão geral do estudo

Descrição detalhada

Background and Rationale

Retrograde intrarenal surgery (RIRS) and ureteroscopy (URS) are widely used minimally invasive procedures for the treatment of upper urinary tract stones. These procedures require continuous irrigation to maintain endoscopic visibility, which may result in substantial elevations in intrarenal pressure (IRP). Elevated IRP can induce intrarenal backflow (IRB), involving the movement of renal pelvic fluid into the renal parenchyma, venous circulation, lymphatic system, and surrounding interstitial tissue.

Experimental studies have demonstrated that elevated IRP may be associated with intrarenal backflow and renal parenchymal alterations. Previous porcine MRI studies have demonstrated regional distribution of intrarenal backflow, suggesting that pressure-related effects may involve specific anatomical regions of the kidney.

Although the relationship between elevated IRP and infectious complications following ureteroscopy has received increasing attention, the potential long-term structural and functional consequences of repeated ureteroscopic procedures remain insufficiently investigated. In particular, it is unknown whether repeated exposure to elevated intrarenal pressure is associated with persistent regional parenchymal alterations, including fibrosis, atrophy, or impaired renal function.

Study Objectives

The primary objective of BackFlow2 is to investigate potential structural and functional renal alterations in patients with a history of repeated unilateral ureteroscopic procedures for urinary stone disease.

The study aims to:

Assess regional renal parenchymal characteristics using multiparametric magnetic resonance imaging (MRI).

Evaluate renal parenchymal stiffness using ultrasound shear-wave elastography as a potential indicator of fibrotic changes.

Assess split renal function and renal scarring using technetium-99m dimercaptosuccinic acid (⁹⁹ᵐTc-DMSA) scintigraphy.

Compare imaging findings between the previously instrumented kidney and the contralateral kidney within individual participants.

Compare renal imaging parameters and inter-renal differences between patients and healthy controls.

Study Design and Population

BackFlow2 is an exploratory, observational, cross-sectional study conducted at Lillebaelt Hospital, Vejle, Denmark.

The study aims to enrol 20 adult participants, comprising 10 patients with a history of repeated unilateral ureteroscopic procedures and 10 healthy controls.

Eligible patients are aged 18-75 years and must have undergone at least three ureteroscopic procedures (RIRS/URS/URSL) involving the same kidney, with no more than one previous ureteroscopic procedure involving the contralateral kidney. More than one month must have elapsed since the most recent procedure before study examinations.

Healthy controls are aged 35-75 years, have serum creatinine levels within the normal reference range, and have no history of ureteroscopy or known renal disease.

Participants with conditions potentially affecting renal structure or function, or interfering with imaging interpretation, are excluded according to predefined eligibility criteria.

Patients are recruited from the Department of Urology through clinical screening and review of previous ureteroscopic procedures and medical records. Healthy controls are recruited through voluntary participation.

All participants provide written informed consent before undergoing study-specific examinations.

Study Procedures

All participants undergo a multimodal assessment of renal structure and function, comprising serum creatinine measurement, multiparametric MRI, bilateral renal ultrasound elastography, and ⁹⁹ᵐTc-DMSA scintigraphy.

  1. Renal Function Assessment

    Serum creatinine is measured before the imaging examinations to assess overall renal function. In healthy controls, serum creatinine within the normal reference range is required to confirm eligibility.

  2. Multiparametric Renal MRI

    Renal MRI is performed using a 1.5T Philips Ingenia MRI system without intravenous contrast administration.

    The imaging protocol includes:

    T1 mapping using a gradient-echo turbo field echo (GRE TFE) sequence.

    Heavily T2-weighted three-dimensional coronal imaging using a turbo spin-echo (TSE) sequence.

    Diffusion-weighted imaging (DWI) using single-shot echo-planar imaging (EPI) with 14 b-values.

    T2*-weighted imaging using a gradient-echo (GRE) sequence.

    Renal arterial flow imaging using a gradient-echo (GRE) sequence.

    Both kidneys are examined to assess regional differences in renal parenchymal structure and functional imaging characteristics.

    Regions of interest are defined in selected anatomical regions of both kidneys to facilitate intraindividual and between-group comparisons.

  3. Renal Ultrasound Elastography

    Bilateral renal ultrasound shear-wave elastography is performed using a Mindray Resona I9 diagnostic ultrasound system (Mindray, Shenzhen, China) to assess regional renal parenchymal stiffness.

    Three repeated measurements are obtained in each of five predefined anatomical regions per kidney: apical, lateroapical, lateral, lateroinferior, and inferior.

    Regional stiffness measurements are compared between the previously instrumented and contralateral kidneys and between patients and healthy controls.

    Ultrasound elastography is used as a complementary imaging method to investigate potential regional parenchymal alterations associated with fibrosis.

  4. Renal DMSA Scintigraphy

Renal scintigraphy is performed approximately two hours after intravenous administration of 100 MBq ⁹⁹ᵐTc-DMSA.

Imaging is acquired using a Siemens Symbia Intevo SPECT system equipped with low-energy high-resolution collimators.

Static anterior and posterior renal images are obtained to quantify split renal function using the geometric mean of tracer uptake.

Additional single-photon emission computed tomography (SPECT) imaging is performed to assess the presence and anatomical distribution of renal cortical defects consistent with scarring.

Scintigraphic findings are compared between kidneys and between study groups and evaluated in relation to regional MRI and ultrasound elastography findings.

Statistical Analysis

Statistical analyses will focus on intraindividual and between-group differences in renal structure and function.

Linear mixed-effects models (LMMs) will be used in the statistical analysis, accounting for the correlation between repeated regional measurements obtained from kidneys within the same participant.

The models will assess differences between the previously instrumented and contralateral kidneys in patients and compare imaging parameters between patients and healthy controls.

Regional findings from MRI, ultrasound elastography, and DMSA scintigraphy will be evaluated for anatomical correspondence.

The study is exploratory, with a limited sample size. Statistical findings will be interpreted with consideration of effect estimates, uncertainty, and the potential for confounding. Observed associations will not be considered evidence of causality.

Ethical Considerations

The study was approved by the Regional Committee on Health Research Ethics, Southern Denmark (approval number S-20240065).

All participants provide written informed consent before undergoing study-specific examinations.

MRI and ultrasound examinations are non-invasive, and MRI is performed without intravenous contrast administration. DMSA scintigraphy involves exposure to a low dose of ionising radiation.

Study data are handled in accordance with applicable data protection regulations.

The study is intended to provide preliminary clinical evidence regarding potential long-term renal structural and functional alterations following repeated ureteroscopic procedures and to inform the design of future investigations.

Tipo de estudo

Observacional

Inscrição (Estimado)

20

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Vejle, Dinamarca, 7100
        • Urological Research Unit, Lillebaelt Hospital, Vejle

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

The study population comprises 20 adults: 10 patients aged 18-75 years with a history of at least three unilateral ureteroscopic procedures (RIRS/URSL/URS), and 10 healthy controls aged 35-75 years with normal renal function and no history of ureteroscopy. Patients are recruited from the urological department at Lillebaelt Hospital, Vejle, while healthy controls are recruited through voluntary participation.

Descrição

Patiet group:

Inclusion Criteria:

  • Age 18-75 years.
  • History of ≥3 retrograde intrarenal surgery (RIRS) or ureteroscopy (URS/URSL) procedures on the affected kidney.
  • At least one month since the most recent RIRS/URS procedure at the time of examination.
  • Legally competent and able to understand the study information and provide informed consent.

Exclusion Criteria:

  • Bilateral stone disease with more than one previous ureteroscopic procedure on the contralateral kidney.
  • Known acute or chronic urinary tract infection (UTI).
  • History of multiple percutaneous nephrolithotomy (PCNL) procedures.
  • Known medical renal disease, including metabolic stone disorders such as renal tubular acidosis, primary hyperoxaluria, nephrocalcinosis, or medullary sponge kidney.
  • Solitary kidney
  • Contraindications to MRI, including MRI-incompatible implants or foreign bodies, or claustrophobia preventing examination.
  • Renal anatomical variants or focal abnormalities that may interfere with imaging analysis, including horseshoe kidney, large or multiple renal cysts, or focal renal lesions.
  • Pregnancy.

Healthy controls:

Inclusion Criteria:

  • Age 35-75 years.
  • Serum creatinine within the normal reference range.
  • Legally competent and able to understand the study information and provide informed consent

Exclusion Criteria:

  • Known renal disease, diabetes mellitus, or untreated hypertension.
  • History of ureteroscopy.
  • Active urinary tract infection (UTI) or history of upper urinary tract infections.
  • Contraindications to MRI, including MRI-incompatible implants or foreign bodies, or claustrophobia preventing examination.
  • Known renal anatomical variants or focal abnormalities that may interfere with imaging analysis, including horseshoe kidney, large or multiple renal cysts, or focal renal lesions.
  • Pregnancy.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_CONTROL
  • Perspectivas de Tempo: CROSS_SECTIONAL

Coortes e Intervenções

Grupo / Coorte
Patients with repeated unilateral ureteroscopic procedures
Healthy controls

Renally healthy individuals.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Renal Parenchymal Structural and Functional Assessment by Multiparametric MRI
Prazo: Baseline (single MRI examination during the study visit).

Renal structure and function are assessed using multiparametric 1.5T MRI, including T1 mapping (GRE TFE), heavily T2-weighted 3D imaging (TSE), diffusion-weighted imaging (DWI; 14 b-values), T2*-weighted imaging (GRE), and renal arterial flow imaging (GRE). Quantitative measurements include renal parenchymal T1 relaxation times (ms). Regional renal imaging parameters are compared between kidneys within each participant and between patients with repeated unilateral ureteroscopic procedures and healthy controls.

Baseline (single MRI examination during the study visit).
Regional Renal Parenchymal Stiffness Assessed by Ultrasound Elastography
Prazo: Baseline (single ultrasound examination during the study visit).

Renal parenchymal stiffness is assessed bilaterally using ultrasound elastography, with three repeated measurements obtained in five predefined regions of each kidney. Regional stiffness values are compared between kidneys within each participant and between patients with repeated unilateral ureteroscopic procedures and healthy controls.

Baseline (single ultrasound examination during the study visit).
Renal Cortical Scarring Assessed by 99mTc-DMSA SPECT
Prazo: Baseline (single scintigraphic examination during the study visit).

Renal cortical abnormalities consistent with scarring are assessed using 99mTc-DMSA single-photon emission computed tomography (SPECT). The presence and anatomical distribution of cortical defects are evaluated in both kidneys and compared between patients with repeated unilateral ureteroscopic procedures and healthy controls.

Baseline (single scintigraphic examination during the study visit).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Estimated Glomerular Filtration Rate (eGFR)
Prazo: Baseline (blood sampling within 30 days before the imaging examination for the healthy controls and on the day of examination for the patients)

Estimated glomerular filtration rate is calculated from serum creatinine to assess global renal function and compare renal function between patients with repeated unilateral ureteroscopic procedures and healthy controls. It alse serves as an eligible criteria for the healthy controls.

Baseline (blood sampling within 30 days before the imaging examination for the healthy controls and on the day of examination for the patients)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Emmeli G Lykkegaard, MD, Urological Research Unit, Lillebealt Hospital, Vejle

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de março de 2025

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

28 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de outubro de 2026

Primeira postagem (Real)

3 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

All participant data are handled in accordance with the EU General Data Protection Regulation (GDPR) and applicable Danish data protection legislation. Study data are securely stored, and access to individual participant data is restricted to authorised members of the research team. Identifiable participant data will not be shared with external parties.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever